Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A

The lysosomal storage disorder (LSD) metachromatic leukodystrophy (MLD) is caused by a deficiency of the soluble, lysosomal hydrolase arylsulfatase A (ASA). The disease is characterized by accumulation of 3-O-sulfogalactosylceramide (sulfatide), progressive demyelination of the nervous system and pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of controlled release 2017-05, Vol.253, p.1-10
Hauptverfasser:	Schuster, Tilman, Mühlstein, Astrid, Yaghootfam, Claudia, Maksimenko, Olga, Shipulo, Elena, Gelperina, Svetlana, Kreuter, Jörg, Gieselmann, Volkmar, Matzner, Ulrich
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Avidin - chemistry Biotinylation Blood-brain barrier Brain - metabolism Cerebroside-Sulfatase - administration & dosage Cerebroside-Sulfatase - chemistry Cerebroside-Sulfatase - genetics Cerebroside-Sulfatase - pharmacokinetics Enzyme replacement therapy Female Lactic Acid - chemistry Leukodystrophy, Metachromatic - drug therapy Leukodystrophy, Metachromatic - metabolism Lysosomal storage disease Metachromatic leukodystrophy Mice, Knockout Nanoparticles - administration & dosage Nanoparticles - chemistry Poloxamer - administration & dosage Poloxamer - chemistry Poloxamer - pharmacokinetics Polyesters - chemistry Polyglycolic Acid - chemistry Polymeric nanoparticles Polysorbates - administration & dosage Polysorbates - chemistry Polysorbates - pharmacokinetics Serum Albumin, Human - chemistry Surface-Active Agents - administration & dosage Surface-Active Agents - chemistry Surface-Active Agents - pharmacokinetics Surfactant coating
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!